Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors
April 07, 2020 08:01 ET
|
Ocugen
MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
Ocugen Provides Business Update and Full Year 2019 Financial Results
March 27, 2020 07:30 ET
|
Ocugen
Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020 Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., March 27, 2020 (GLOBE...
Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update
March 20, 2020 07:30 ET
|
Ocugen
MALVERN, Pa., March 20, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)
March 03, 2020 07:30 ET
|
Ocugen
MALVERN, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference
February 10, 2020 07:30 ET
|
Ocugen
MALVERN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD
December 09, 2019 09:29 ET
|
Ocugen
MALVERN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), ), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of...
Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights
November 08, 2019 07:30 ET
|
Ocugen
MALVERN, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of...
Ocugen Announces Warrant Restructuring
November 06, 2019 09:01 ET
|
Ocugen
MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of...
Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards
November 04, 2019 07:30 ET
|
Ocugen
MALVERN, Pa., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of...
Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
October 25, 2019 07:30 ET
|
Ocugen
MALVERN, Pa., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of...